178813-77-9

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloro-3-fluorobenzaldehyde is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-Dichloro-3-fluorobenzaldehyde serves as an intermediate in the synthesis of compounds used in crop protection and pest management. Its role in creating effective and targeted agrochemicals is vital for enhancing agricultural productivity and sustainability.
Used in Research and Development:
2,6-Dichloro-3-fluorobenzaldehyde is utilized as a research compound in scientific studies and development programs. It aids chemists and researchers in exploring new chemical reactions and understanding the properties of related compounds, thus fostering innovation in the chemical sciences.

Upstream product

• 98-87-3 benzylidene dichloride 
• 178813-79-1 2,6-dichloro-3-fluorobenzal chloride 
• 68-12-2 N,N-dimethyl-formamide 
• 1227611-90-6 (2,6-dichloro-3-fluorophenyl)methanol 
• 107-31-3 Methyl formate 
• 1435-48-9 1,3-dichloro-4-fluorobenzene 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 178813-78-0 2,6?dichloro?3?fluorobenzoic acid 

Downstream Products

• 1227611-86-0 ((S)-1-{5-bromo-3-[(S)-1-(2,6-dichloro-3-fluorophenyl)ethyl]pyrrolo[2,3-b]pyridine-1-carbonyl}-3-methylbutyl)carbamic acid 9H-fluoren-9-ylmethyl ester 
• 1227611-87-1 ((S)-1-{5-bromo-3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethyl]pyrrolo[2,3-b]pyridine-1-carbonyl}-3-methylbutyl)carbamic acid 9H-fluoren-9-ylmethyl ester 
• 1227611-46-2 3-(4-{3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyrazol-1-yl)-azetidine-1-carboxamide 
• 1227611-70-2 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1227611-78-0 4-(4-{3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyrazol-1-yl)cyclohexanone 
• 1227611-38-2 2-amino-1-(4-{3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-3,6-dihydro-2H-pyridin-1-yl)-2-methylpropan-1-one 
• 1227611-57-5 5-{3-[(S)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-3,6-dihydro-2H-pyridine-1-carboxamide 
• 1227611-39-3 4-{3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-3,6-dihydro-2H-pyridine-1-sulfonic acid amide 
• 1227611-26-8 4-{3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-3,6-dihydro-2H-pyridine-1-carboxamide 
• 1227611-45-1 3-(4-{3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyrazol-1-yl)-azetidine-1-carbaldehyde 
• 1227611-44-0 5-(1-azetidin-3-yl-1H-pyrazol-4-yl)-3-[1-(2,6-dichloro-3-fluoro-phenyl)ethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1227611-56-4 3-[(S)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-(1,2,5,6-tetrahydropyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1227611-31-5 4-{3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-3,6-dihydro-2H-pyridine-1-carbaldehyde 
• 1227611-25-7 3-[1-(2,6-dichloro-3-fluorophenyl)-ethyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine 

Relevant academic research and scientific papers

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

PIEZO1 AGONISTS FOR THE PROMOTION OF BONE FORMATION

Disclosed herein are Piezo 1 agonists. Also disclosed herein are methods of stimulating tissue anabolism in a subject comprising administering an effective amount of a Piezo 1 agonist and methods for chemically mimicking mechanical stimulation of a cell expressing Piezo 1 comprising contacting a cell expressing Piezo1 with an effective amount of a Piezo 1 agonist.

Method of fluorination using iodonium ylides

A process for fluorination of aromatic compounds employing iodonium ylides and applicable to radiofluorination using 18F is described. Processes, intermediates, reagents and radiolabelled compounds are described.

Methods for preparing 2,6-dichloro-3-fluorobenzaldehyde and fluoroquinolone compound

The invention relates to methods for preparing 2,6-dichloro-3-fluorobenzaldehyde and a fluoroquinolone compound.2,4-dichloro-5-fluorobenzoic acid is taken as the raw material and is in reaction in a concentrated sulfuric acid solvent under the action of a bromization reagent to generate 2,4-dichloro-3-bromine-5-fluorobenzoic acid; the 2,4-dichloro-3-bromine-5-fluorobenzoic acid and Grignard reagent isopropylmagnesium chloride are in halogen-metal exchange reaction to prepare a 2,4-dichloro-3-bromine-5-fluorobenzoic acid Grignard reagent, and the 2,4-dichloro-3-bromine-5-fluorobenzoic acid Grignard reagent is further in reaction with DMF and heated for decarboxylation to obtain the target compound 2,6-dichloro-3-fluorobenzaldehyde. Compared with the prior art, the methods for preparing the 2,6-dichloro-3-fluorobenzaldehyde and the fluoroquinolone compound have the advantages that the raw materials are easy to get, the operation technology is simple, the cost is low and the like, and the methods are favorable for industrialization scale production and have larger implement values and social and economic benefits.

FUSED BICYCLIC KINASE INHIBITORS

Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention.

Fused Bicyclic Kinase Inhibitors

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

FUSED BICYCLIC KINASE INHIBITORS

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as but not limited to tumors driven at least in part by at least one of RON, MET, IR, IGF-1 R, or ALK. This Abstract is not limiting of the invention.

AZAINDOLE DERIVATIVES AS KINASE INHIBITORS

This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES

Compounds of Formula I, as shown below and defined herein:(I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met.

Herbicidal compositions based on 2,6-dichloro-3-fluoro-benzonitrile, and new intermediates

The invention relates to the use of the known compound 2,6-dichloro-3-fluoro-benzonitrile as active compound in selectively-herbicidal compositions, and to new preparation processes and new intermediates for the preparation of this compound.